Clinical Trials Logo

Hemodilution clinical trials

View clinical trials related to Hemodilution.

Filter by:
  • None
  • Page 1

NCT ID: NCT06399536 Not yet recruiting - Clinical trials for Transfusion Related Complication

Individualized ANH for Non-cardiac Surgery

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

In this trial, we proposed an individualized acute normovolemic hemodilution (ANH), and conduct a randomized controlled trial to testify the effect of individualized ANH on red cells requirement for non-cardiac surgeries with anticipating major blood loss in adults.

NCT ID: NCT05606536 Recruiting - Microcirculation Clinical Trials

The Impact of Intra-operative Fluid Infusion Rate on Microcirculation

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Intraoperative fluid therapy (IFT) is an integral part of anesthesia care during surgery. Its main indication is the optimization of oxygen supply to the tissues. For elective surgery that is not associated with higher blood loss and a long period of preoperative fasting, including fluids IFT is dosed to cover the basal daily need for fluids. However, it is not clear whether this fluid dose is optimal. Surgery is a stress factor that leads, among other things, to damage of the endothelial glycocalyx (EG). EG binds a significant amount of plasma, which is released during EG destruction and causes relative hemodilution. Isovolumic hemodilution is an established intraoperative procedure that serves to better control bleeding in procedures where bleeding is expected. However, partial hemodilution occurs even with standard IFT, and even when fluids are hardly given at all. Flow parameters in microcirculation have not yet been described depending on IFT conduction. The parameters of the microcirculation reflect its functioning, which will consequently affect the postoperative phase of the patient's moaning and clinical outcome.

NCT ID: NCT04870073 Withdrawn - Clinical trials for Coronary Artery Disease

Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery

RAPPER-MAN
Start date: September 21, 2022
Phase: Phase 3
Study type: Interventional

Hemodilution reduces concentrations of blood constituents: concentration of hemoglobin, red blood cells (hematocrit), physiological ions and coagulation factors that can contribute to impaired hemostasis and increasing the risk of perioperative blood transfusions. This pilot study will assess the feasibility of a large RCT to evaluate 2 techniques for reducing hemodilution during cardiac surgery: 1) retrograde autologous priming and 2) intraoperative mannitol. The aim of this pilot trial is to demonstrate feasibility of a larger trial to evaluate whether retrograde autologous priming and/or mannitol are superior to conventional priming alone.

NCT ID: NCT02318355 Completed - Hemorrhage Clinical Trials

Proving Hemodilution in a Human Model for Class I Hemorrhage

Start date: November 2013
Phase: N/A
Study type: Interventional

This study is a randomized control trial in volunteer blood donors to quantify the effect of blood loss and subsequent crystalloid infusion on hemoglobin and markers of resuscitation such as base deficit and lactate.

NCT ID: NCT02179827 Withdrawn - Hemodilution Clinical Trials

Performance of Non-Invasive Monitors During ANH

Start date: November 2022
Phase:
Study type: Observational

The aim of this study is to assess the responsiveness of the standard minimally invasive hemodynamic monitors used in the operating room to known changes in the intravascular volume status that occur during blood removal and volume replacement with three different standard fluids used during ANH.

NCT ID: NCT01382134 Completed - Clinical trials for Platelet Dysfunction

Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction

Start date: July 2011
Phase: N/A
Study type: Interventional

Study hypothesis: Desmopressin (DDAVP) can improve platelet function under influence of aspirin, hemodilution and mild hypothermia Mild hypothermia (34-35oC) is known to cause platelet dysfunction. This could lead to increased surgical bleeding and increased transfusion requirement during surgery. Although this hypothermia-induced platelet dysfunction seems to be reversible with warming, this is not always possible or desirable. Desmopressin (DDAVP) is a drug which has proven efficacy in improving platelet function in uraemic and cirrhosis patients, and in reducing blood loss in selected surgeries. In a recent study, we have found that subcutaneous injection of 1.5 mcg (1/10th the usual dose) is already sufficient to fully reverse the platelet dysfunction seen at 32oC. We have demonstrated in another study that prolongation of the bleeding time in a 20% hemodiluted sample predicts increased postoperative bleeding after total knee replacement. We have therefore designed this study as a follow up to our last two studies on DDAVP and hypothermia, to investigate whether hemodilution affects hypothermia induced platelet dysfunction and the response to DDAVP. In addition, another common cause of perioperative platelet dysfunction is the intake of COX inhibitors, particularly aspirin by patients. Therefor the effect of aspirin on hypothermia induced platelet dysfunction and the response to DDAVP, will also be investigated.

NCT ID: NCT00637468 Terminated - Stroke Clinical Trials

EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye

EAGLE
Start date: September 2002
Phase: Phase 3
Study type: Interventional

The aim of the EAGLE Study is to compare the efficacy of conservative medical treatment and local intraarterial fibrinolysis in patients with central retinal artery occlusion and to evaluate benefit and risk for the patient of both therapies.